ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1531

The Changing Face of Septic Arthritis Complicating Rheumatoid Arthritis in the Era of Biotherapies. Retrospective Single-Center Study over 35 Years

Jean-Jacques Dubost1, Bruno Pereira2, Anne Tournadre3, Zuzana Tatar1, Marion Couderc1 and Martin Soubrier1, 1Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, 2Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, 3Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Arthritis, Biologic drugs, infection and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a risk factor for septic arthritis (SA), and anti-TNF therapy doubles the risk of SA. The purpose of this study was to see whether the frequency and features of SA complicating RA have changed over the last 35 years.

Methods: This retrospective single-center study included the full register of all patients hospitalized at the rheumatology department of Clermont-Ferrand—CHU between 1979 and 2013 for septic arthritis bacteriologically documented by synovial fluid and/or blood culture samples. The periods 1979–2002 (period before biotherapies) and 2003–2013 (last decade in the era of biotherapies) were compared.

Results: Between 1979 and 2013, 64/514 (12.5%) SA presented with a RA—21/153 (13.7%) in the 2003–2013 period and 43/361 (11.9%) in the 1979–2002 period. Over the past decade, median age of SA–RA patients increased (61 vs 68 years; p<0.02) and predominant gender became males (52% vs 40%). The features of the RA remained unchanged: history (18 years (8–29) vs 16 (8–25)), rheumatoid factor (95% vs 87%), and corticosteroids (91% vs 81%) at the same mean dose (10 mg/d). 71% in the period before biotherapies and 63% in the last decade received a DMARD. Over the last decade 24% (vs 0; p<0.003) of patients received a biologic DMARD: etanercept (n=2), adalimumab (n=1), rituximab (n=1), tocilizumab (n=1). Proportion of polyarticular infection had decreased (9.5% vs 37%; p<0.02), down to the same level as SA-non-RA cases (8%).  Proportion of S. aureus infections had stabilized (62% vs 74%) in SA-RA patients but was higher than SA-non-RA (47% and 53%). MRSA infections became more frequent in SA-RA (31% vs 6%; p<0.05) in contrast to SA-non-RA cases (8% vs 16%; ns). Gram-negative bacilli infections have tended to become more frequent (19% vs 5%; p=0.08). Blood cultures less often tested positive (29% vs 47%; ns). Mortality rates has fallen slightly (5% vs 9%; ns), in contrast to SA-non-RA cases (7% vs 6%; ns).

Conclusion: This study brings reassuring findings—in the era of biotherapies, the frequency of septic arthritis complicating rheumatoid arthritis has stabilized, and the most severe septic polyarticular forms are on the decline.


Disclosure: J. J. Dubost, None; B. Pereira, None; A. Tournadre, None; Z. Tatar, None; M. Couderc, None; M. Soubrier, None.

To cite this abstract in AMA style:

Dubost JJ, Pereira B, Tournadre A, Tatar Z, Couderc M, Soubrier M. The Changing Face of Septic Arthritis Complicating Rheumatoid Arthritis in the Era of Biotherapies. Retrospective Single-Center Study over 35 Years [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-changing-face-of-septic-arthritis-complicating-rheumatoid-arthritis-in-the-era-of-biotherapies-retrospective-single-center-study-over-35-years/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-changing-face-of-septic-arthritis-complicating-rheumatoid-arthritis-in-the-era-of-biotherapies-retrospective-single-center-study-over-35-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology